{"id":"W4402561249","doi":"10.1016/j.annonc.2024.08.1005","title":"944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Oncolytics Biotech; Coherus Biosciences; Celgene; Rakuten Medical; Pfizer; Incyte; Break Through Cancer; Relay Therapeutics; Seagen; Agios Pharmaceuticals; BeiGene; Tizona Therapeutics; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; Sanofi; Exelixis; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; AbbVie; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Open label; Head and neck; Head and neck cancer; Immunotherapy; Randomized controlled trial; Cancer; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009853776,0.001553165,0.002234251,0.0003561256,0.0003449596,0.001060019,0.0009445673,0.001461283,0.006371466],"category_scores_gemma":[0.0008394839,0.000548765,0.001405053,0.0003505393,0.0008473147,0.001218147,0.0003596674,0.003077809,0.001474101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008293632,"about_ca_system_score_gemma":0.000830401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009703957,"about_ca_topic_score_gemma":0.002068512,"domain_scores_codex":[0.9996649,0.0001431899,0.00001561883,0.00007481361,0.00002723585,0.00007422136],"domain_scores_gemma":[0.9996374,0.00009637182,0.00006728909,0.00002803112,0.00002047998,0.0001504465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9542293,0.008974298,0.0005245974,0.0004853329,0.0008012959,0.00004151456,0.00004505117,0.0005356031,0.004409424,0.0001373555,0.001002178,0.02881408],"study_design_scores_gemma":[0.880932,0.1147976,0.001557295,0.00003195923,0.0005039395,0.00004433872,0.0000237176,0.0006574352,0.0006146102,0.0001690572,0.0006514204,0.00001655752],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905827,0.003119195,0.0004431596,0.0005374331,0.0004721314,0.001783387,0.0008060744,0.0001242736,0.002131681],"genre_scores_gemma":[0.98829,0.002307073,0.001435222,0.0009082299,0.0003287949,0.002034497,0.001185698,0.00002727157,0.003483283],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006371466,"threshold_uncertainty_score":0.02131468,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1036179366882806,"score_gpt":0.4185586573027306,"score_spread":0.31494072061445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}